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ABBREVIATURES 
 
ATMP: Advanced Therapy Medicinal Product  
sCTMP: Somatic Cell Therapy Medicinal Product 
GTMP: Gene Therapy Medicinal Product  
TEP: Tissue-Engineered Product   
CATP: Combined Advanced Therapy Products  
FDA: Food and Drug Administration  
MHLW: Ministry of Health Labour and Welfare  
EMA: European Medicines Agency  
EU: European Union 
ICH: International Conference on Harmonization 
PMDA: Pharmaceutical and Medical Devices Agency  
CAT: Committee for Advanced Therapies  
GLP: Good Laboratory Practice 
GCP: Good Clinical Practice  
GMP: Good Manufacturing Practice  
GVP: Good Pharmacovigilance Practice 
PASS: Post-Authorization Safety Studies 
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ABSTRACT  
 
Introduction: New therapies with genes, tissues and cells have taken the emerging field 
for the treatment to many diseases. Advances on stem cell therapy research have led to 
international regulatory agencies to harmonize and regulate the development of new 
medicines with stem cells.  
Sources of data: European Medicines Agency on 15
th
 September 2012. 
Areas of agreement: Cell therapy medicinal products should be subjected to the same 
regulatory principles than any other medicine.   
Areas of controversy: Their technical requirements for quality, safety and efficacy 
must be more specific and stringent than other biological products and medicines. 
Growing points: Cell therapy medicinal products are at the cutting edge of innovation 
and offer a major hope for various diseases for which there are limited or no therapeutic 
options. 
Areas timely for developing research: The development of cell therapy medicinal 
products constitutes an alternative therapeutic strategy to conventional clinical therapy, 
for which no effective cure was previously available. 
 
KEY WORDS:  regulatory agencies, advanced therapies and cell therapy. 
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INTRODUCTION  
 
Advanced Therapy Medicinal Products (ATMP) are a new medicinal product category 
including: Somatic Cell Therapy Medical Products (sCTMP), Gene Therapy Medical 
Products (GTMP) and Tissue Engineered Products (TEP). Cells, genes and engineered 
tissues are regarded as new active substances in the development of medicines.  Aside 
from the well-established bone marrow transplantation, advances in cell therapy in the 
last decade, have promoted the development of multiple lines of research for the 
development of a sCTMP.  
The application of cells as pharmacological active substance has the purpose to repair, 
replace or recover the biological function of damaged tissue or organs. Cell therapy is 
an alternative for the treatment of both high prevalent chronic and rare diseases 
including immune
1
 and cardiovascular diseases
2
,
 
diabetes and their complications
3-6
, 
neurodegenerative disorders
7
, inflammatory diseases such as Crohn's disease
8
, 
musculoskeletal diseases
9
, cancer
10
, etc. 
 
Development of new medicines for the treatment of untreated disease aims to improve 
the patient’s quality of life with new and specific therapies either addressed to the right 
target thus minimizing side effects or using new strategies and mechanisms of action 
which open new therapeutic avenues. In this context Europe has pioneered the 
development of advanced therapies; however most of the preclinical and clinical 
research is investigator-driven and less-frequently involving spin-offs and small biotech 
companies. Academic institutions and small and medium enterprises are not so familiar 
with regulatory issues as conventional pharmaceutical industry. In this manuscript we 
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aim to describe the regulatory issues to consider during the different steps in the process 
of innovation for new advanced therapies as sCTMP. 
 
The design, development and authorization of a medicine are a long and complex 
process. Regulation needs to be applied from the early stages of development of a new 
medicine to ensure that it meets the requirements of quality, efficacy, and safety for 
administration in humans. This applies to all medicinal products whether of chemical or 
biological origin
11
. In Europe, sCTMP meet the definition of a medicinal product as 
described in Directive 2001/83/EC
12
 amended by two subsequent directives 
(2003/63/EC and 2009/120/EC)
13,14
 and completed by Regulation (EC) No 1394/2207
15
. 
sCTMP have a specific regulation to harmonize legal framework and to promote 
research in this field.  
 
This review describes and discusses the different stages in the development of a 
sCTMP, and both regulatory and practical requirements, from a European perspective. 
 
1. REGULATORY AGENCIES 
 
The three most important regulatory agencies that regulate the development of a 
medicine for human use are: European Medicines Agency (EMA) in the European 
Union (EU), Food and Drug Administration (FDA) in United States and Ministry of 
Health Labour and Welfare (MHLW) in Japan.  
 
Coordination of technical requirements at the international level is achieved through the 
International Conference on Harmonization of Technical Requirements for Registration 
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of Pharmaceuticals for Human Use (ICH). Its main mission is to achieve management 
in the technical guidelines on the quality, safety and efficacy of new medicines
16
 (Table 
1). This organization brings together regulatory authorities, pharmaceutical industry and 
scientific experts from the United States, Japan and Europe.  
Regulatory agencies also review the indications for use, content of the package leaflet, 
dosage, side effects, warnings and contraindications. Finally, they also ensure post-
regulatory Pharmacovigilance. 
 
……….. Table 1 near here……… 
 
European Medicines Agency (EMA) 
 
EMA is a decentralized agency of the EU located in London (www.ema.eu). Its main 
responsibility is the protection and promotion of human and animal health, through the 
evaluation and supervision of medicines for human and veterinary use
17
. This 
evaluation is done by experts from the national medicines agencies from the EU 
countries who are members of different committees within the EMA: Committee for 
Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for 
Veterinary Use (CVMP), Pediatric Committee (PDCO), Committee for Orphan 
Medicinal Products (COMP), Committee on Herbal Medicinal Products (HMPC) and 
Committee for Advanced Therapies (CAT). In July 2012 a new committee was created 
at the EMA, the Pharmacovigilance and Risk Assessment Committee (PRAC). 
Scientific Committees also receive input from different Working Parties (experts in 
different areas). Through these committees, EMA provides scientific advice for the 
development of new medicines. 
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The CAT started working in 2009 in order to promote the development of advanced 
therapies and to the pursuit of innovation in new treatments with ATMP. The CAT 
consists of experts in the field of ATMP nominated by the EU Member States, the 
CHMP and the European Commission. Its main responsibility is to prepare a draft 
opinion on the quality, safety, and efficacy of a product for the final approval each 
ATMP marketing authorization application submitted to the EMA, before the CHMP 
adopts the final opinion on the medicine concerned. CAT offers a query system for the 
classification of ATMP. This procedure is optional, free of charge and may take place at 
any stage of the development of a sCTMP or any ATMP in advance of applying for a 
marketing authorization
18,19
. CAT is involved in the certification of quality and/or non-
clinical data, in the development of scientific guidelines and reflection papers and in 
regulatory procedures and scientific articles. Regulatory aspects for cell-based therapy 
medicinal products will be described in this paper in more detail.  
 
Food and Drug Administration (FDA) 
 
FDA is the agency responsible for authorizing the marketing of new medicines in the 
United States of America
20,21
. The FDA's Center for Biologics Evaluation and Research 
is responsible for ensuring the safety, purity, potency and effectiveness of many 
biological products (cells, genes, tissues, blood components and derivatives, vaccines, 
etc) for the prevention, diagnosis and treatment of human diseases. Because of their 
biological origin cell therapy medicinal products are regulated in the Code of Federal 
Regulations under Title 21 PART 1271, Human Cells, Tissues, and Cellular And 
Tissue-Based Products
22,23
. In order to promote the development of cell therapy 
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medicinal products, the FDA has formed a working group with the pharmaceutical 
industry called Critical Path Initiative to act in a pro-active fashion regarding the 
development of new medicinal products. 
 
Ministry of Health, Labour and Welfare (MHLW) 
 
MHLW is the Japanese consumer protection agency. The Pharmaceutical and Medical 
Devices Agency (PMDA) is responsible for the scientific evaluation of applications for 
marketing authorization for new medicines in Japan. The development of a cell therapy 
medicinal product for human use in Japan is governed by the Guideline on Clinical 
Research Using Human Stem Cells (July 3, 2006 amended in full, November 1, 2010). 
PMDA has a committee of experts in medicine and bioethics to review all human stem 
cell clinical research. This committee is based in this guideline and the latest scientific 
findings
24
. On the other hand there is a specific regulation for clinical trials (Phases I to 
III, and postregulatory), regulated by the Pharmaceutical Affairs Law (1960 Law 145).  
 
ADVANCED THERAPIES IN EUROPE 
 
In order to harmonize the technical aspects of new medicines, in terms of quality, safety 
and efficacy, the EU proposed a plan of action for the development of new biotech 
medicines. This plan included genes and cells products as a biological medicinal 
product. ATMP have to fulfill the same scientific and regulatory standards as all other 
medicinal products. Directive 2001/83/EC
12
 (Annex I, part IV) consolidated all the 
regulation of biotechnological products for human use, and defines for first time the 
terms: gene therapy medicinal products and somatic cell therapy medicinal products. In 
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2003, Directive 2003/63/EC
13
 amended Directive 2001/83/EC on medicinal products 
for human use. Later, in 2008 the regulation of biological medicines was updated, and 
included tissue engineering to the area of advanced therapies, Regulation (EC) No 
1394/2007
15
. This regulation lays down specific rules concerning the authorization, 
supervision and pharmacovigilance of ATMP. A transitional period was defined to 
comply with these requirements. In the case of cell and gene therapy the period ended 
December 30, 2011. However, for tissue engineering products a four-year period was 
defined that will end on December 30, 2012.  
In 2009, Commission Directive 2009/120/EC
14
 was indeed the legal document that was 
established after the Regulation (EC) No 1394/2007 to implement the changes into 
2001/83/EC. Any organization (pharmaceutical industry, hospitals, public or private 
research) should comply with the requirements of this regulation from January 1, 2013, 
for the development of any ATMP of use in humans. According to the European 
regulation
12,13,14,15
 ATMPs include sCTMP, GTMP, TEP, and Combined Advanced 
Therapy Products (CATP).  
 
In addition, Directive 2004/23/EC
25
, Directive 2006/17/EC
26 
and Directive 
2006/86/EC
27
 describe the quality and safety standards for the donation, procurement, 
testing, processing, preservation, storage, and distribution of human tissues and cells. 
These directives apply to products classified as no ATMP (when cells have the same 
essential function in the donor as in the recent and when they do not subject to a 
substantial manipulation)
15
 and therefore no medicines. For ATMP, these directives 
only apply in relation to donation, procurement and testing of biological samples which 
will be obtained from the cells, genes and/or tissues. With regard to ATMP with blood 
components or blood cells, Directive 2002/98/EC
28
 will also apply.  
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Somatic Cell Therapy Medicinal Products (sCTMP) 
 
sCTMP are defined as biological medicinal products which contains or consists of cells 
or tissues that have been subject to substantial manipulation so that biological 
characteristics, physiological functions or structural properties relevant for the intended 
clinical use have been altered, or of cells or tissues that are not intended to be used for 
the same essential function in the recipient and the donor or/and they are presented as 
having properties for, or is used in or administered to human beings, with a view to 
treating, preventing or diagnosing a disease through the pharmacological, 
immunological or metabolic action of its cells or tissues
12,14
.  
On term of regulation the following manipulations are considered “ no substantial ”: 
cutting, crushing, shaping, centrifuging, soaking in antibiotic or antimicrobial solutions, 
sterilizations, irradiation, cell separation, cell concentration, etc… all of them are 
described in the Annex 1, Regulation No 1394/2007
15
. In contrast processes that modify 
biological characteristics, physiological functions or structural properties of the cells or 
tissues are considered “ substantial”
29
.  
 
Active substances for a sCTMP may be manipulated cells, cellular components, lysate 
cells, proliferating cells and genetically modified cells. The materials in combination 
with cells should be considered as starting materials and thus form part of the active 
substance
14
. Cells may be of autologous, allogeneic or xenogeneic origin. Autologous 
products are those in which donor and recipient of cells is the same person. Allogeneic 
products are derived from cells or tissues removed from a donor and applied to another 
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person. A xenogeneic cellular product includes animal viable somatic cell adapted for 
application into a human recipient. 
 
Gene Therapy Medicinal Products (GTMP) 
 
GTMP is defined as biological medicinal product containing an active substance which 
contains or consists of a recombinant nucleic acid used in, or administered to human 
beings with a view to regulating, repairing, replacing, adding or deleting a genetic 
sequence
12,14
. Its therapeutic, prophylactic or diagnostic effect relates directly to the 
recombinant nucleic acid sequence it contains, or to the product of genetic expression of 
this sequence. GTMP shall not include vaccines against infectious diseases. 
 
Tissue-engineered Products (TEP) 
 
TEP are defined as a product that contains or consists of engineered cells or tissues used 
for regenerating, repairing or replacing a human tissue (Chapter 1 - Article 2, 
Regulation No 1394/2007)
15
. The biological origin of the cells and tissues may be 
human or animal. These products contain viable or non-viable cells or tissues and 
additional substances, such as cellular products, bio-molecules, biomaterials, chemical 
substances, scaffolds or matrices.  
As mentioned above, as for sCTMP, cells or tissues are considered engineered if they 
fulfil at least one of the following conditions: cells or tissues have been subject to 
substantial manipulation, so that biological characteristics, physiological functions or 
structural properties relevant for the intended regeneration, repair or replacement are 
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achieved; or the cells or tissues are not intended to be used for the same essential 
function or functions in the recipient as in the donor
15
. 
 
Combined Advanced Therapy Products (CATP) 
 
 CATP are products that incorporating as an integral part of the product, one or more 
medical devices or one or more active implantable medical devices. These products 
must contain viable cells or tissues, or its cellular or tissue part containing non-viable 
cells or tissues must be liable to act upon the human body with action that can be 
considered as primary to that of the devices referred to
15
. 
 
A medical device or an active implantable medical device should meet the essential 
requirements described in Directive 93/42/EEC
30
 concerning medical devices and 
Directive 90/385/EEC
31
 relating to active implantable medical devices, in order to 
ensure an appropriate level of quality and safety. Both directives were amended by 
Directive 2007/47/EC
32
. EN/ISO 10993-18
33
 and EN/ISO 10993-19
34
 describe some 
guidelines about additional substance, which should be identified and characterized in 
chemical and physical terms (porosity, density, microscopic structure and particular 
size). Safety, suitability and biocompatibility of all structural components and additional 
substances are a must in developing these products. CATP may also incorporate 
structural components, which are not identical or used in the same way as in a medical 
device. All structural components should be fully characterized and evaluated for their 
suitability for the intended use. Any medical device used in addition or combined to the 
cells should be described and their function underpinned by means of chemical, 
biological, physical and mechanical properties
35
. 
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STAGES OF RESEARCH ON THE DEVELOPMENT OF A sCTMP IN 
EUROPE 
 
In contrast with the conventional innovation model in the pharmaceutical industry, 
advanced therapies are usually developed by small and medium enterprises and 
academia (hospitals, universities, etc). In any case their development includes several 
phases: experimental observations, preclinical phase (animal testing under Good 
Laboratory Practice
36
 conditions) (GLP) and clinical trials (Phases I to IV under Good 
Clinical Practice
37
 (GCP), Good Manufacturing Practice
38
 (GMP) and Good 
Pharmacovigilance Practice
39
 (GVP), prior to an application for registration and 
marketing). All these phases must address the critical points in the development of 
cellular therapy. Clinical development should be approved by national medicines 
agencies, marketing authorization applications should go through the EMA with the 
exception of national hospital exemption, also in compliance with national 
requirements. The Regulation (EC) 1394/2007 describes that it is possible to prepare a 
sCTMP in a hospital under the exclusive professional responsibility of a medical 
practitioner for an individual patient. sCTMP will be manufacture on a non-routine 
basis according to specific quality standards. The competent authority of the member 
state of Union Europe should authorize the manufacturing of these products and each 
member state should authorize a hospital exemption clause, ensuring the compliance of 
traceability and pharmacovigilance with European requirements
15
. National agencies are 
currently developing rules for hospital exemption with quality requirements similar to 
those applied by EMA. 
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The main critical points in the development of a new sCTMP are: selection of cellular 
biological sample, cell type and its production process including biopsy; active 
substance formulation (qualitative and quantitative composition), selection of 
pharmaceutical form (cell concentration of the medicinal product; route of 
administration; dose (single-dose, multi-dose); detailed instructions for use, application, 
implantation or administration; dose-response relationship; shelf-life and stability; 
pharmacological properties; quality properties of product; assessment of adverse 
reactions and evaluation of the risk-benefit balance that must always be positive
12,13,14, 
15,35,40
.  Both national agencies and CAT can provide regulatory advice during the 
development of a sCTMP
41
. 
On the other hand the EMA has published several guides that describe regulatory 
aspects for the development of a sCTMP, CHMP/410896/06
35
, 
CHMP/CPWP/708420/09
40 
and CHMP/CPWP/83508/09
42
 among others. 
 
Experimental Observations 
 
At this stage of development, experimental observations focused in basic laboratory 
research should determine the active (either differentiated progenitor or stem cells) and 
establish a tentative mechanism of action of the sCTMP to be developed.  
The active ingredients (cells) are classified in consonance with the tissue localization 
from which they are obtained and their function (embryonic stem cells may be obtained 
from the first stages of embryo development; adult stem cells are found in the bone 
marrow, adipose tissue, etc; mononuclear cells from the bone marrow, etc), by their 
potentiality (pluripotential, etc). Currently there is much diversity in the name of these 
cell derived products. There is no unified naming convention, which would facilitate 
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research in this area giving common information sources in the development of a 
product. Nomenclature for these active substances should be standardized at the 
European level, with a consensus for all sCTMP. 
 
Pre-clinical Research 
 
Preclinical development of a sCTMP refers to the set of studies on efficacy and safety 
of the active substance (cells) to be performed in biological systems distinct to the 
human that may give substantial information to address a Phase I-IIa pilot study. These 
may include in-vitro work with cellular models, preclinical experiments using animal 
cells in animal models and preclinical work using human cells in immunocompromised 
mice
43
. Although there are no perfect models that mimic the human disease, these 
approaches may provide enough information for ethical committees and regulatory 
agencies to decide for further development on the basis of the proper balance between 
risk and benefit for a specific situation.  
The selection of animal models and species should be scientifically justified. The phase 
of preclinical research is focused on toxicity and assessment of the biological activity of 
the cells
44
, through pharmacodynamic, pharmacological, pharmacokinetic, 
biodistribution, tumourigenicity and interactions with other cellular or not components 
studies. 
Non-clinical studies performed in animals and physiological models in the laboratory 
aim to analyze the physic-chemical properties and behavior of the compound both in 
vivo and in vitro. When relevant animal models cannot be developed, ex vivo and/or in 
vitro studies may replace animal studies. Data from preclinical studies must be 
interpreted in terms of the animal species used, since human stem cells are very 
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different from an animal model. Usually, two or more species (a rodent and non-rodent) 
are used in these experiments because the medicine application could affect differently. 
 
Non-clinical studies should be carried out in conformity with the provisions related to 
GLP laid down in Directive 2004/10/EC
36
 and Directive 2004/9/EC
45
 on the inspection 
and verification of GLP. Animal tests are designed not only to show the safety and 
proof of concept for efficacy of the new medicinal product, but also to assess its 
biodistribution, pharmacodynamics and toxicity. In contrast with small molecules and 
biological, the control of the amount of drug absorbed into the blood, its chemical 
breakdown in the body, the short-, mid- and long-term toxicity, its breakdown products 
(metabolites) and the rate of excretion usually measured in preclinical studies
46
 are 
difficult to evaluate with cellular medicines. Non-clinical aspects are described in 
guideline 35 of the ICH S6 and should be considered. The number of animals, their 
genders, the frequency and duration of monitoring should be appropriate to detect 
possible adverse effects
35
. An effort should be made to introduce new tests that respond 
to these questions when using cells as medicines. 
 
GLP are a set of principles that provides a framework within which laboratory studies 
are planned, performed, monitored, recorded, reported, and archived to ensure the 
reliability of data generated within a compliant laboratory
47
. A key feature of GLP is the 
generation of quality-control methods and data management within the cell culture 
laboratory
48
. GLP principles were set by the Organization for Economic Co-operation 
and Development (OECD). This organization has established the Mutual Acceptance of 
Data system in OECD member countries for the mutual acceptance of non-clinical 
safety study data
49
. For purposes of assessment and other uses related to the protection 
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of human being and his environment other member countries should accept GLP 
principles. 
 The OECD has issued a series of recommendations for compliance with the GLP. 
These guidelines focus on the assessment of chemicals for very different applications, 
and also apply to medicines.  
 
Clinical Research (and follow-up) 
 
Clinical trials can be classified according to their purpose, phase I, phase II, phase III 
and Phase IV.  
 
Clinical trials in Phase I are the first step in investigating a substance or new drug in 
humans. They are based to evaluate its safety, determine a safe dosage range, and 
identify side effects. This phase provides the approximate profile of safety and tolerance 
of the product. In advanced therapies would be a safety and feasibility study on patients. 
For instance, it would not be ethical to conduct a gene therapy trial on healthy human 
volunteers. Whilst Phase one primary end-points must respond safety and efficacy, 
surrogate endpoints may check for the efficacy. Phase II studies include initial clinical 
research treatment effect. Clinical trials of this phase are carried out on patients with the 
clinical entity of interest. Its main objective is getting to know the dose with the best 
risk/benefit profile. Phase III studies or pivotal trials are designed to evaluate the safety 
and efficacy of the experimental drug trying to reproduce the conditions of common use 
and considering the therapeutic alternatives available for the disease studied. Phase IV 
convenes pharmacovigilance and additional efficacy studies and correspond to post 
marketing/post authorization studies with marketed medicines. The objective at this 
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stage is to study the detection of long-term side effects, and possible effects of drug on 
the disease itself or studies of morbidity and mortality (Fig 1).   
 
…. Figure 1 near here…….. 
 
Clinical application of sCTMP should be subject to the same regulatory principles as for 
any other biotechnological medicinal product for human use
50
, although their technical 
requirements for quality, safety and efficacy must be more specific
51
. 
 
 
Requirements to conduct clinical trials in the EU are provided by Directive 
2001/20/EC
37
. Clinical trials have to be designed and performed according to the 
overarching principles and ethical requirements laid down in GCP as laid down in 
Directive 2005/28/EC
52
 where principles and detailed guidelines for good clinical 
practice as regards investigational medicinal products for human use are described.   
 
GCP are a set of ethical and scientific requirements of internationally recognized quality 
that must be met in planning, conducting, recording and reporting of clinical trials 
involving humans. Their compliance ensures the protection of human rights, safety and 
welfare will of trial subjects and the reliability of clinical trial results. These studies 
have to be made respecting the principles of the Helsinki Declaration prepared by the 
Assembly of World Medical Congress, Helsinki, Finland in 1964 and revisited 
periodically with the main goal of protecting patient rights. GCP stipulates the clinical 
trial process, including protocol and Case Report Form design, analyses planning, as 
well as analyzing and preparing interim and final clinical trial/study reports. In contrast 
with small molecule clinical trials, sCTMP cannot be given to volunteers in order to 
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demonstrate safety and feasibility. Therefore, “proof-of-concept” pilot studies consist in 
testing the cellular medicine in a small group of patients with an untreatable disease or 
condition and demonstrate safety and feasibility whilst observing efficacy. Phase II and 
III may be randomized double-blinded with placebo group. These clinical trials focus on 
the study of the cellular function, their distribution, dose, effect and above all safety. A 
recent position paper by the European Science Foundation has made a proposal for a 
revision of the “Clinical Trial Directive (2001/20/EC)” and other recommendations to 
facilitate clinical trials (Dec 2011).  
 
Clinical trials on the use of sCTMP are underway for a wide variety of diseases, 
however different cell types are used, most of them badly defined. Bone marrow 
mononuclear cells are a heterogeneous mixture of cells
53
, umbilical cord blood
54
 are 
mostly but not only hematopoietic, mesenchymal
55
 stromal cells from different origins 
are selected by their capacity to adhere to the culture plastic dish, etc. Most clinical 
trials in cell therapy currently ongoing are phase I/II studies, and about 15562 studies 
are registered in www.ClinicalTrials.gov.  
 
 
Manufacturing cell-based medicinal products 
 
Technical requirements for sCTMP are based primarily on quality, safety and efficacy 
aspects. In contrast to traditional medicines, sCTMP have different and more specific 
characteristics. The risks analysis of the whole manufacturing process, the quality of 
manufacturing aspects and non-clinical and clinical development are aspects that should 
be taken into account when manufacturing a sCTMP
35
.  
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It is also necessary to conduct a risk analysis covering the entire process. Risks 
associated with a sCTMP are highly dependent on the biological characteristics of the 
product. Risk factors that may include, among others could be: origin of cells, level of 
manipulation, combination of cells with bioactive molecules or materials structural, 
management or use mode
12,14
, etc. Recommendations of the risk analysis is part of the 
dossier for a marketing authorization application, described in 
EMA/CHMP/CPWP/708420/2009
40
, guideline on the risk-based approach according to 
annex I, part IV of Dir. 2001/83/EC applied to advanced therapy medicinal products. 
Regarding   safety and efficacy follow-up - risk management, was published a 
guideline, EMEA/149995/200856. 
 
All batches of a sCTMP manufactured for the clinical phase should be carried out under 
GMP standards. sCTMP in clinical phase is considered to be an investigational 
medicinal product, then it should be in compliance with the principles of GMP
 
(Directive 2003/94/EC)
38
. Therefore requirements for installations, staff, equipment, 
documentation, production, quality control, batch release, labeling, etc should be 
manufactured and checked in compliance with the requirements of GMP guidelines.  
In practical terms these standards are described in EudraLex-Volume 4 GMP guidelines, 
and consists of: Part I - Basic Requirements for Medicinal Products (9 chapter), Part II - 
Basic Requirements for Active Substances used as Starting Materials, Part III - GMP 
related documents and 20 Annexes
57
. The manufacture of sCTMP must be carried out 
as described in the 9 chapters of Part I, in addition to that referred in Annexes: 1- 
Manufactured of sterile medicinal products; 2- Manufacture of biological medicinal 
products for Human use; 8- Sampling of starting and packaging materials, 13- 
Manufactured of Investigational Medicinal Products; 14- Manufactured of Products 
Page 20 of 40
http://mc.manuscriptcentral.com/bmb
Manuscripts submitted to British Medical Bulletin
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 21
Derived from Human Blood or Human Plasma; 15- Qualification and validation; 16- 
Certification by a Qualified Person and Batch Release, 17-Parametric Release, 19- 
Reference and Retention Samples. Likewise, detailed clinical guidelines for GCP have 
been described in EudraLex-Volume 10 which contains six guidance documents 
applying to clinical trials
58
. 
 
The manufacturing process of a sCTMP for clinical use must be consistent and 
reproducible providing sufficient quality to the final product for patient safety. GMP 
applies to both production and quality control of the medicinal product.  These 
guidelines ensure that medicinal products are consistently produced and controlled to 
the quality standards appropriate to their intended use and according to the requirements 
of the product specification
59
. 
Concerning quality control requirements it is important to check that the active 
substance of sCTMP is viable, so at the end of the process the final product for the 
patient, should not include terminal sterilization, purification steps and/or viral removal. 
Therefore, the quality of the starting materials deri ed from animal or human origin 
should be analyzed. These materials comprise excipients and the donor of biological 
sample for the active substance. The quality criteria required by the European regulation 
for the characterization of the final product requires considerations such as, the identity 
of the cellular and non-cellular components; cell purity; impurities of product or related 
process; impurities as adventitious agents; potency and tumourigenicity
35
.  
The manufacturing process of sCTMP should be carefully designed and validated to 
ensure product consistency and repeatability of the cell culture process. These products 
are highly heterogeneous due to their origin, starting material, degree of in vitro 
manipulation and manufacturing process
60
. 
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During the manufacture of a sCTMP considered an aseptic procedure, all manufacturing 
processes should be validated including: validation of sterility, validation of aseptic 
process, validation of microbiological environmental monitoring and validation of 
cleaning process
61
. Thorough study of each process involved in the manufacture of a 
sCTMP should be made to ensure their safety in terms of quality.  
 
Authorization, Registration and Marketing 
 
The evaluation of the medicines for their authorization and commercialization is 
regulated by Directive 2001/83/EC and Regulation (EC) No 726/2004
62
, amended by 
Regulation (EU)  No 1235/2010 
63
, as regards pharmacovigilance of medicinal products 
for human use. This regulation develops and improves European procedures for the 
authorization, supervision and pharmacovigilance of medicinal products for human and 
veterinary use.  
 
There three procedures to approve new medicinal products: the centralized procedure, 
generating a single marketing authorization valid throughout the EU, the decentralized 
procedure, in which the application is submitted to member states selected by the 
applicant and mutual recognition procedure, when the reference member state has 
already issued a marketing authorization. However, the centralized authorization 
procedure is compulsory for medicinal products manufactured by biotechnological 
methods and for advanced therapy medicinal products such as sCTMP. 
 
The CAT is involved in all scientific advice on ATMPs and in the regulatory procedures 
of the classification and the certification procedures. CAT is responsible for the 
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evaluation of the marketing authorization applications for sCTMP
19
. Following the 
CHMP scientific assessment the European Commission issues a decision that is 
published in the Official Journal of the European Community, which is valid for all EU 
countries. 
The marketing authorization is valid for five years and may be renewed. Once it has 
been renewed, it is valid indefinitely, unless the Commission chooses not to validate 
again for another five years.  The approval decision will be taken based on the scientific 
criteria of quality, safety and efficacy in evaluation. These three criteria allow 
evaluating the risk-benefit balance of all medicines.   
On the other hand, in order to give micro, small and medium-sized enterprises, EMA 
published the Regulation (EC) No 668/2009
64
, with regard to the evaluation and 
certification of quality and non-clinical data relating to ATMP developed (describes in 
two guidelines, EMA/CAT/486831/2008/corr
65
 and EMA/CAT/418458/2008/corr.
66
), 
implementing Regulation (EC) No 1394/2007.   
 
Post-authorization  
 
Once the marketing authorization is requested and approved, EMA may request post-
authorization studies, the authorization may be conditionally granted. Post authorization 
studies focus on pharmacovigilance; it is the science for the assessment, awareness and 
prevention of any side effects or possible adverse reactions associated with medicines. 
This phase is regulated by Directive 2010/84/EU
67
, which define el new concept of a 
post authorization safety studies (PASS). PASS have the aim at collecting data to study 
for the assessment of the safety and efficacy of the sCTMP with the purpose of generate 
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additional information on the effects of medicines in with usual conditions of clinical 
practice and to complete the information obtained during phases I, II and III. 
PASS can be non-interventional trial or observational and clinical trial (phase IV). With 
sCTMP are carried out a PASS with the aim of identifying, characterizing or 
quantifying a safety hazard of cell medicine, confirming the safety profile of these 
products or of measuring the effectiveness of risk management measures
67
. 
 
Post authorization phase shall be carried out in conformity with the provisions related to 
GVP. GVP are a set of measures drawn up to facilitate the performance of 
pharmacovigilance in the EU. The guidelines on GVP are divided into 16 modules, each 
of which covers one major process in pharmacovigilance
39
. It released modules III and 
X for consultation in June 2012. Each of the seven modules released covers one major 
process in the safety monitoring of medicines. The full set of 16 final modules is 
scheduled to be available by early 2013.  After marketing authorisation has been 
granted, any change to the data in the dossier shall be submitted to the competent 
authorities in accordance with the requirements of Commission Regulations (EC) No 
1084/2003
68
 and (EC) No 1085/2003
69
. 
 
DISCUSSION   
 
Application, administration or implantation of human cells is opening new avenues in 
the search for the treatment of critical diseases, some of which are as yet incurable
70
.  In 
the last years, encouraging observations at the preclinical level have promoted the 
development of cell therapies that are in distinct clinical phases. Several if not all 
clinical trials use cells from adult origin, most of them mesenchymal-like cells. As 
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compared with hundreds of clinical trials with other medicines only a limited number of 
sCTMP are translated into products for clinical development and marketing 
authorization (Table 2).  
The development and manufacture of conventional medicines is performed by physical 
and chemical techniques with consistency and robustness. However, sCTMP 
development is a technique that still far to reach such strength. sCTMP should take into 
account the variability of the production process, the risk of exogenous contamination 
(microbiological, viral….)and variability of quality control techniques. Since active 
principals are active substances and not chemical compounds.  
 
The European framework for the development of sCTMP aims to provide an increased 
international competitiveness of these products, the European regulation in the field of 
advanced therapies ensure that all patients receive drug treatment quality. 
We anticipate that a deeper knowledge of regulatory issues among clinical investigators 
and small biotech enterprise will expand this field that holds the promise for so far 
untreatable diseases.  
-- Table 2 near here---------- 
Since 2003, the cells and/or cellular component are considered as medicines, so since 
then, public institutions such as hospitals and universities, and private companies have 
been forced to change their methods of clinical and non-clinical research and their 
development. All this change has been accompanied by the update on the EU regulatory 
field. The legal and technical requirements necessary for the development of new 
medicines as sCTMP, are framed by common guidelines for the entire EU. 
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TABLES  
 
Table 1. Categories and topic codes to the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). 
 
 
CATEGORY CODE APLICATIONS 
QUALITY Q 
Concerning the stability studies,  
the definition of relevant limits for impurities 
 testing and a focus on product quality 
SEGURITY S Guidelines for potential hazards such as carcinogenicity,  genotoxicity and reproductive toxicity. 
EFICACY E 
For the design, development, safety and reporting 
 of clinical trials. There are also guidelines for medicinal  
products derived from biotechnology processes,  
use of pharmacogenetics and genomic techniques 
 for the production of more specific drugs. 
MULTIDISCIPLINARY M 
For cross-cutting themes that do not conform 
 to only one of the above categories (quality, safety and 
efficacy). 
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Table 2. Examples of Advanced Therapy Medical Product marketed in the European 
Union, United States of America, Japan and Canada. 
 
 
 
COUNTRY PRODUCT (Company) CELLS TYPE DESCRIPTION 
European Union  ChondoCelect
®
  
(TiGenix NV) 
Autologous cultured 
chondrocytes 
Indicated for the repair of cartilage lesions of the 
cartilage of the knee in adults. Used only in case 
of injury of the femoral condyle cartilage of the 
knee (end of the femur). 
USA 
Carticel®  
(Genzyme 
Corporation) 
Autologous cultured 
chondrocytes 
 A cell therapy medicine product indicated for the 
repair of symptomatic cartilage defects of the 
femoral condyle, caused by acute or repetitive 
traumatic the knee of adults who have not 
responded to a prior arthroscopic or other surgical 
repair procedure. 
Epicel®  
(Genzyme 
Corporation) 
Cultured keratinocytes  
A sheet of autologous keratinocytes used to 
replace the epidermal or top layer of skin on 
severely burned patients. Human keratinocytes are 
grown on a layer of irradiated mouse cells 
(xenogenic), 
Provengene® 
(Dendreon) 
Autologous CD54+ cells 
activated 
with PAPGM-CSF 
An autologous cellular immunotherapy indicated 
for the treatment of asymptomatic or minimally 
symptomatic metastatic castrate resistant 
(hormone refractory) prostate cancer. 
Apligraf®  
(Organogenesis) 
A collagen matrix and 
living keratinocytes 
 and fibroblast cells 
Used to heal ulcers such as diabetic foot and 
venous leg ulcers  
Japan Laviv
® 
(Fibrocell Science) 
Autologous  cultured 
fibroblasts   
Anti-aging treatment; Fibroblasts are then re-
injected into wrinkles. 
Canada Prochymal
®
 
(Osiris) Mesenchymal stromal cells 
 A cellular suspension for the treatment of acute 
graft-vs-host disease (GvHD) in children. 
Prochymal is made up of bone marrow stem cells 
derived from an adult donor and is designed to 
control inflammation, promote tissue regeneration 
and prevent scar formation. 
 
Accessed here for detailed information: http://www.tigenix.com; 
http://www.genzyme.com; http://www.dendreon.com; http://www.organogenesis.com; 
http://www.fibrocellscience.com;http://www.osiris.com. 
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DEVELOPMENT OF 
EXPERIMENTAL PRE CLINICAL
SOMATIC CELL THERAPY MEDICINAL PRODUCT
CLINICAL AUTHORIZATION 
OBSERVATIONS
-
RESEARCH RESEARCH
 
AND
MARKETING 
Good
Laboratory 
Practice (GLP)
Good Clinical
Practice (GCP);
Good Manufacturing
Practice (GMP)
Good Manufacturing
Practice (GMP);
Good Pharmacovigilance 
Practice (GVP)  
D/2004/10/EC
D/2004/9/EC
D/2001/83/EC
D/2003/63/EC
D/2009/120/EC
D/2001/20/EC
D/2005/28/EC
Regulation No 726/2004
Regulation No 1235/2010
Regulation No 668/2009
Regulation No 1084/2003
Regulation No 1085/2003
D/2003/94/EC
D/2004/23/EC
D/2006/17/EC
D/2006/86/EC
D/2002/98/EC
  
D/2001/83/EC
D/2003/63/EC
D/2009/120/EC
D/2010/84/CE
D/2010/84/EU
Regulation No 1394/2007
Figure 1. Regulatory issues in the development of a cellular medicine in European Union.
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